Core Viewpoint - Rebio Biotech-B (06938) has successfully listed its shares at a price of HKD 57.97, raising approximately HKD 1.702 billion, with a notable initial increase of 29.38% to HKD 75 per share [1] Company Overview - Rebio Biotech is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1] - The company has a core product, RBD4059, aimed at treating thrombotic diseases, and has a pipeline of seven self-developed drug assets currently in clinical trials [1] Clinical Pipeline - The clinical pipeline includes treatments for cardiovascular, metabolic, renal, and liver diseases, with four products currently in Phase 2 clinical trials [1] - In addition to RBD4059, the company is advancing other clinical-stage products such as RBD5044 and RBD1016 [1] - RBD5044 is the second siRNA drug globally to enter clinical development targeting APOC3, a protein involved in lipid metabolism [1] - RBD1016 aims for functional cure of chronic hepatitis B (CHB) through its action on HBsAg and is a differentiated siRNA candidate for coronary heart disease (CHD) [1] Preclinical Projects - Beyond the clinical pipeline, the company has over 20 preclinical projects planned for advancement into clinical development [1]
瑞博生物-B首挂上市 早盘高开29.38% 公司为小核酸制药领域领军企业